FDA approval yesterday of heart failure drug sacubitril/valsartan (Entresto), previously known as LCZ696, and the pending approval of two PCSK9 inhibitors this summer has reinvigorated
LINK TO REPORT: Innovation drives progress,” suggests the US Food and Drug Administration (FDA) in its report on the 41 new molecular entities and new
Published: March 16, 2015, Employee Benefit News Authors: Cheryl Larson, Vice President, Midwest Business Group on Health and Randy Vogenberg, Principal, Integrated Healthcare Institute Earlier
The impact of specialty drugs continues to increase in both drug utilization and spend. In 2012, specialty drug spend accounted for approximately $87 billion, or
Mailing Address:
211 S. Clark #2749, Chicago, IL 60604
Phone: 312-372-9090
